5 Results for "

D-2HG

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "D-2HG" in MCE Product Catalog:

7
7 Cited Publications
Cat. No.: HY-104042
CAS No.: 1644545-52-7
Purity:  99.87%
Synonyms: AG-881
Research Areas:  

Cancer

Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K. Vorasidenib can be used for the study of grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation [2].
Cat. No.: HY-156158
CAS No.: 2749568-16-7
Research Areas:  

Cancer

IDH2 R140Q-IN-2 (compound 36) is an an orally active IDH2 R140Q inhibitor (IC50: 29 nM). IDH2 R140Q-IN-2 reduces D2HG production in TF-1 cell lines expressing mutant IDH2 R140Q (IC50: 10 nM). IDH2 R140Q-IN-2 suppresses D2HG levels in tumor tissue. IDH2 R140Q-IN-2 can be used for research of acute myeloid leukemia (AML) .
Cat. No.: HY-E71043
Research Areas:  

Others

D-2-Hydroxyglutarate Dehydrogenase, Acidaminococcus fermentans (EC 1.1.99.39) is a special NAD-dependent enzyme which reacts with D2HG specifically and converts D-2-hydroxyglutarate (D2HG) to α-ketoglutarate.
Cat. No.: HY-145743
CAS No.: 1111233-06-7
Research Areas:  

Cancer

CP-17 is a potent and selective IDH2/R140Q inhibitor with an IC50 of 40.75 nM. CP-17 exhibits excellent selectivity of >55-fold against the wild-type IDH2. CP-17 exhibits robust D-2-HG suppression activity in TF-1 (IDH2/R140Q) cells and reverses the cellular differentiation block induced by the R140Q mutation. CP-17 can be used for acute myeloid leukemia (AML) research .
Cat. No.: HY-104042R
CAS No.: 1644545-52-7
Synonyms: AG-881 (Standard)
Vorasidenib (Standard) is the analytical standard of Vorasidenib (HY-104042). This product is intended for research and analytical applications. Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K. Vorasidenib can be used for the study of grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation [2].